Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer
Shuji Ogino(Broad Institute), Charles S. Fuchs(University of Southern California), Jeffrey A. Meyerhardt(CancerCare), Mohan Brahmandam(Dana-Farber Cancer Institute), Mami Cantor(Dana-Farber Cancer Institute), Chungdak Namgyal(Dana-Farber Cancer Institute), David P. Ryan(East Carolina University), Massimo Loda(Cornell University), Kate Kinsella(Dana-Farber Cancer Institute), Jeffrey W. Clark(Massachusetts General Hospital), Peter C. Enzinger(Dana-Farber Cancer Institute), Matthew H. Kulke(Moffitt Cancer Center), Takako Kawasaki(Dana-Farber Cancer Institute), Ann Michelini(Dana-Farber Cancer Institute)
Cited by 157
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k